Literature DB >> 1549219

Hypotension-induced vasopressin release distinguishes between pure autonomic failure and multiple system atrophy with autonomic failure.

H Kaufmann1, E Oribe, M Miller, P Knott, M Wiltshire-Clement, M D Yahr.   

Abstract

To investigate whether activation of afferent and central baroreceptor pathways could differentiate between pure autonomic failure (PAF) and multiple system atrophy with autonomic failure (MSA), we determined the effect of upright tilt on circulating levels of vasopressin in patients with PAF and patients with MSA. We also studied 14 normal subjects, nine of whom developed acute hypotension due to vasovagal syncope. In patients with PAF and in normal subjects with vasovagal syncope, upright tilt induced marked hypotension and a pronounced increase in the plasma concentration of vasopressin (1.1 +/- 0.3 to 38.0 +/- 8.0 pmol/l in PAF and 1.0 +/- 0.2 to 27.4 +/- 7.2 pmol/l in vasovagal syncope, p less than 0.005 for both). In patients with MSA, upright tilt also elicited profound hypotension but circulating levels of vasopressin increased little (0.5 +/- 0.1 to 1.5 +/- 0.3 pmol/l, p less than 0.05). During upright tilt, the plasma concentration of norepinephrine significantly increased in normal subjects but did not increase in patients with autonomic failure. Our results indicate that afferent and central baroreceptor pathways involved in vasopressin release are normal in patients with PAF but are impaired in patients with MSA. Thus, measurement of baroreceptor-mediated vasopressin release appears to provide a clear marker to differentiate between patients with PAF and patients with MSA.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1549219     DOI: 10.1212/wnl.42.3.590

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  27 in total

1.  Clinical and physiological characteristics of autonomic failure with Parkinson's disease.

Authors:  Y Niimi; T Ieda; M Hirayama; Y Koike; G Sobue; Y Hasegawa; A Takahashi
Journal:  Clin Auton Res       Date:  1999-06       Impact factor: 4.435

Review 2.  Multiple system atrophy: pathophysiology and management.

Authors:  G K Wenning; S Braune
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

Review 3.  Multiple system atrophy.

Authors:  H U Rehman
Journal:  Postgrad Med J       Date:  2001-06       Impact factor: 2.401

4.  Afferent baroreflex failure in familial dysautonomia.

Authors:  Lucy Norcliffe-Kaufmann; Felicia Axelrod; Horacio Kaufmann
Journal:  Neurology       Date:  2010-11-23       Impact factor: 9.910

Review 5.  Brain SPECT imaging in multiple system atrophy.

Authors:  R Cilia; G Marotta; R Benti; G Pezzoli; A Antonini
Journal:  J Neural Transm (Vienna)       Date:  2005-12       Impact factor: 3.575

6.  Nocturnal blood pressure dipping in the hypertension of autonomic failure.

Authors:  Luis E Okamoto; Alfredo Gamboa; Cyndya Shibao; Bonnie K Black; André Diedrich; Satish R Raj; David Robertson; Italo Biaggioni
Journal:  Hypertension       Date:  2008-12-01       Impact factor: 10.190

Review 7.  Management of neurogenic orthostatic hypotension in patients with autonomic failure.

Authors:  Christoph Schroeder; Jens Jordan; Horacio Kaufmann
Journal:  Drugs       Date:  2013-08       Impact factor: 9.546

8.  Orthostatic heart rate changes in patients with autonomic failure caused by neurodegenerative synucleinopathies.

Authors:  Lucy Norcliffe-Kaufmann; Horacio Kaufmann; Jose-Alberto Palma; Cyndya A Shibao; Italo Biaggioni; Amanda C Peltier; Wolfgang Singer; Phillip A Low; David S Goldstein; Christopher H Gibbons; Roy Freeman; David Robertson
Journal:  Ann Neurol       Date:  2018-03-10       Impact factor: 10.422

9.  Baroreceptor denervation presenting as part of a vagal mononeuropathy.

Authors:  D L Jardine; I C Melton; S I Bennett; I G Crozier; I M Donaldson; H Ikram
Journal:  Clin Auton Res       Date:  2000-04       Impact factor: 4.435

Review 10.  Brainstem in multiple system atrophy: clinicopathological correlations.

Authors:  Eduardo E Benarroch
Journal:  Cell Mol Neurobiol       Date:  2003-10       Impact factor: 5.046

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.